原发性<em>TP53</em>突变型胃癌的病理特征及患者预后的影响因素

doi:10.3969/j.issn.1671-7171.2025.02.005

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1243 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical pathological characteristics and prognostic impact of patients with primary TP53 mutated gastric cancer.【Methods】This retrospective study analyzed the clinical data of 68 patients with TP53 mutated gastric cancer (mutation group) and 102 patients with TP53 wild-type gastric cancer (wild-type group). The clinical pathological characteristics of the two groups were compared. Survival curves were plotted using the Kaplan-Meier method, and overall survival (OS) and disease-free survival (DFS) were compared using the Log-rank test. Univariate analysis and Cox regression models were employed to explore the independent factors affecting the prognosis of gastric cancer patients.【Results】Patients in the mutation group with age≥55 a significantly higher proportion of poorly differentiated tumors, advanced (Stage Ⅲ+Ⅳ) TNM staging, lymph node metastasis, and larger tumor size compared to the wild-type group (P<0.05). Survival analysis showed that the 3-year OS and DFS rates of the TP53 mutation group were significantly lower than those of the wild-type group (P<0.05). Univariate Cox regression analysis indicated that differentiation degree, TNM stage, lymph node metastasis, tumor diameter, and TP53 mutation were adverse prognostic factors for gastric cancer; multivariate Cox regression analysis revealed that age, differentiation degree, TNM stage, lymph node metastasis, tumor diameter, and TP53 mutation were independent risk factors for poor prognosis in gastric cancer.【Conclusion】Patients with TP53 mutated gastric cancer exhibit poorer clinical characteristics and prognosis. Age, differentiation degree, TNM stage, lymph node metastasis, tumor diameter, and TP53 mutation are independent prognostic risk factors.

Key words： Genes, p53 Stomach Neoplasms Pathological Conditions,Signs and Symptoms Prognosis

Received: 12 November 2024

PACS:

R735.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JI Chengdong
	LU Xialiang
	ZHAO Wanjun

Cite this article:

JI Chengdong,LU Xialiang,ZHAO Wanjun. Clinical Pathological Characteristics and Prognostic Impact of Primary TP53 Mutated Gastric Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 193-196.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.02.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I2/193

[1] 叶梦楠,武鸿美,梅琰,等. CREM在胃癌中高表达并与患者的不良预后相关[J].南方医科大学学报,2024,44(9):1776-1782.
[2] 张紫涵,陈明明,刘君,等. 基于GEPIA数据库分析胃癌和正常组织的差异表达基因及对预后影响[J].海南医学院学报,2024,30(8):591-596.
[3] 唐豪言,潘正龙,刘小方. TP53基因单核苷酸多态性与原发性肝细胞癌预后的关系[J].天津医药,2023,51(11):1249-1254.
[4] 张娜,周婕,徐锋,等. 地西他滨治疗老年骨髓增生异常综合征的疗效以及与TP53基因突变的相关性[J].实用老年医学,2024,38(3):283-286.
[5] 中华医学会肿瘤学分会早诊早治学组. 胃癌早诊早治中国专家共识(2023版)[J].中华消化外科杂志,2024,23(1):23-36.
[6] 黄京京,毛亮亮,林康明,等. 基于TP53突变型胃癌患者DAXX表达特征的预后模型及其对临床结局的预测价值[J].浙江医学,2024,46(12):1252-1257.
[7] 徐蕾,林国强. TP53基因突变急性髓系白血病患者临床及分子生物学特征分析[J].中国肿瘤临床,2024,51(6):281-286.
[8] 殷金磊,张瑞东. 伴TP53基因突变急性淋巴细胞白血病研究进展[J].中华实用儿科临床杂志,2024,39(5):389-393.
[9] 王伟,周伟. 奥希替尼联合培美曲塞/铂类对表皮生长因子受体合并TP53基因突变的非小细胞肺癌疗效及预后分析[J].中国肿瘤外科杂志,2024,16(2):143-147.
[10] 李小航,李安安,朱宝兴,等. 膀胱尿路上皮癌中TP53、FGFR3和PIK3CA基因突变的临床病理意义[J].临床与实验病理学杂志,2023,39(6):668-674.
[11] 董丽丽,黄赛,赵志艺,等. 奥妥珠单抗联合化疗治疗多线化疗后进展且塞利尼索无效的TP53突变Burkitt淋巴瘤[J].肿瘤药学,2024,14(1):36-39.
[12] 汪正斌,温诚浩,张力. TP53突变在前列腺癌发生发展以及治疗与预后评估中作用的研究进展[J].临床泌尿外科杂志,2024,39(2):167-171.
[13] 李文强,秦旭,胡传宇,等. TP53突变影响口腔鳞癌PD-1表达相关性的临床分析[J].临床口腔医学杂志,2024,40(8):469-471.
[14] 刘瑞琦,王洁,雷超,等. 利用CRISPR/Cas9技术靶向KRAS或TP53突变抑制SW620细胞的增殖[J].现代生物医学进展,2023,23(21):4001-4006.
[15] 陈百川,黄慧君,沈文怡. 伴TP53基因异常骨髓增生异常肿瘤的临床研究进展[J].南京医科大学学报(自然科学版),2024,44(2):271-276.